The APAC region has emerged as a leader in the global clinical trial landscape, attributable to several key factors including a large, diverse patient population with a large proportion of treatment-naïve people, cost effectiveness in conducting clinical trials and a favorable regulatory environment.
China Dominates APAC’s Emergence As Global Trials Hub
39% Of Total Trial Starts In ’23
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a new Citeline White Paper shows.
More from Clinical Trials
More from Geography
• By
Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.
• By
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.